|
11 Companies |
|
8 Products |
|
8 Products |
|
12 Mechanisms of Action |
|
1 Trial |
|
102 News |
|
| 123» |
- | Trial completion, Trial completion date, Trial primary completion date: SOCS: Cushing's Osteoporosis Specificities (clinicaltrials.gov) - Apr 15, 2025
P=N/A, N=50, Completed, Sponsor: University Hospital, Clermont-Ferrand
Recruiting --> Completed | Trial completion date: May 2024 --> Mar 2025 | Trial primary completion date: May 2019 --> Mar 2025
- | Trial completion date, Trial primary completion date: Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=234, Recruiting, Sponsor: Samsung Medical Center
Recruiting --> Completed | Trial completion date: May 2024 --> Mar 2025 | Trial primary completion date: May 2019 --> Mar 2025 Trial completion date: May 2018 --> May 2024 | Trial primary completion date: May 2018 --> May 2020
- | NN1213 / Novo Nordisk
Trial completion: An Investigation Into the Effect of Liquorice Ingestion on the Salivary Cortisol to Cortisone Molar Ratio (clinicaltrials.gov) - Apr 11, 2019
P=N/A, N=12, Completed, Sponsor: The Royal Wolverhampton Hospitals NHS Trust
Trial completion date: May 2018 --> May 2024 | Trial primary completion date: May 2018 --> May 2020 Recruiting --> Completed
- | Trial completion, Trial completion date: 11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=40, Completed, Sponsor: Helsinki University Central Hospital
Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2019
- ||| NN1213 / Novo Nordisk
Biomarker, Trial completion, Surgery: Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery (clinicaltrials.gov) - Jan 24, 2019
P=N/A, N=26, Completed, Sponsor: Corcept Therapeutics
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2019 Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Open-label Study on Treatment of Primary Aldosteronism With Everolimus (clinicaltrials.gov) - Jan 9, 2019
P2, N=12, Completed, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
- | Korlym (mifepristone) / Corcept Therap
Trial completion: RE-KLAIM: Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (clinicaltrials.gov) - Nov 30, 2018
P=N/A, N=24, Completed, Sponsor: Corcept Therapeutics
Recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018 Enrolling by invitation --> Completed
- || NN1213 / Novo Nordisk
Biomarker, Trial completion date, Trial primary completion date, Surgery: Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery (clinicaltrials.gov) - Oct 31, 2018
P=N/A, N=26, Active, not recruiting, Sponsor: Corcept Therapeutics
Enrolling by invitation --> Completed Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018
- || NN1213 / Novo Nordisk
Biomarker, Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Surgery: Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery (clinicaltrials.gov) - Jul 13, 2018
P=N/A, N=26, Active, not recruiting, Sponsor: Corcept Therapeutics
Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018 Recruiting --> Active, not recruiting | N=20 --> 26 | Trial completion date: Dec 2021 --> Sep 2018 | Trial primary completion date: Dec 2020 --> Sep 2018
- | Trial primary completion date: Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism (clinicaltrials.gov) - Mar 2, 2018
P2, N=4, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=20 --> 26 | Trial completion date: Dec 2021 --> Sep 2018 | Trial primary completion date: Dec 2020 --> Sep 2018 Trial primary completion date: Feb 2018 --> Aug 2017
- | Trial completion, Trial completion date, Trial primary completion date: Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism (clinicaltrials.gov) - Feb 28, 2018
P2, N=4, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2018 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2019 --> Feb 2018 | Trial completion date: Jul 2020 --> Feb 2018
- | Trial completion, Enrollment change: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Feb 20, 2018
P=N/A, N=63, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial primary completion date: Jul 2019 --> Feb 2018 | Trial completion date: Jul 2020 --> Feb 2018 Active, not recruiting --> Completed | N=45 --> 63
- Signifor (pasireotide) / Recordati
Enrollment change, Trial withdrawal: SOM230 Ectopic ACTH-producing Tumors (clinicaltrials.gov) - Jan 26, 2018
P2, N=0, Withdrawn, Sponsor: Cedars-Sinai Medical Center
Active, not recruiting --> Completed | N=45 --> 63 N=16 --> 0 | Recruiting --> Withdrawn
- | Trial completion, Trial primary completion date: Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects (clinicaltrials.gov) - Jan 23, 2018
P=N/A, N=60, Completed, Sponsor: Huashan Hospital
N=16 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Dec 2017
- | Trial completion, Enrollment change, Trial primary completion date: T2T@PSU: Tweens to Teens Project at Penn State (clinicaltrials.gov) - Jan 8, 2018
P=N/A, N=188, Completed, Sponsor: Penn State University
Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Dec 2017 Recruiting --> Completed | N=300 --> 188 | Trial primary completion date: Jul 2011 --> Jul 2013
- | Enrollment change, Trial termination, Trial primary completion date: Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome (clinicaltrials.gov) - Dec 22, 2017
P=N/A, N=1, Terminated, Sponsor: University of Aarhus
Recruiting --> Completed | N=300 --> 188 | Trial primary completion date: Jul 2011 --> Jul 2013 N=10 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Nov 2016; Recruitment problems
- | Trial completion: PHA-FMD: Primary Hyperaldosteronism and Ischemia-reperfusion Injury (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=40, Completed, Sponsor: Radboud University
N=10 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Nov 2016; Recruitment problems Enrolling by invitation --> Completed
- Biomarker, Trial primary completion date, Surgery: Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=20, Recruiting, Sponsor: Corcept Therapeutics
Enrolling by invitation --> Completed Trial primary completion date: Jul 2017 --> Dec 2020
- | Minnebro (esaxerenone) / Daiichi Sankyo
Trial completion: Study of CS-3150 in Patients With Primary Aldosteronism (clinicaltrials.gov) - Aug 14, 2017
P=N/A, N=44, Completed, Sponsor: Daiichi Sankyo Co., Ltd.
Trial primary completion date: Jul 2017 --> Dec 2020 Active, not recruiting --> Completed
- | Enrollment open, Trial primary completion date: An Investigation Into the Effect of Liquorice Ingestion on the Salivary Cortisol to Cortisone Molar Ratio (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=12, Recruiting, Sponsor: The Royal Wolverhampton Hospitals NHS Trust
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Oct 2017
- | NN1213 / Novo Nordisk
Trial completion: Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=61, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Oct 2017 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Heart Disease Risk Factors in Major Depression (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=160, Completed, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed Recruiting --> Completed
- | Enrollment closed, Enrollment change, Trial primary completion date: Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism (clinicaltrials.gov) - Jun 9, 2017
P2, N=4, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting | N=66 --> 4 | Trial primary completion date: Jul 2018 --> Jul 2019
- | everolimus / Generic mfg.
New P2 trial: Open-label Study on Treatment of Primary Aldosteronism With Everolimus (clinicaltrials.gov) - Jun 1, 2017
P2, N=12, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- | New trial: SOCS: Cushing's Osteoporosis Specificities (clinicaltrials.gov) - May 22, 2017
P=N/A, N=60, Recruiting, Sponsor: University Hospital, Clermont-Ferrand
- | New trial: OPALE GH: Growth Hormone (GH) in Congenital Adrenal Hyperplasia (clinicaltrials.gov) - May 22, 2017
P=N/A, N=25, Completed, Sponsor: Hospices Civils de Lyon
- Minnebro (esaxerenone) / Daiichi Sankyo
Enrollment closed, Phase classification: Study of CS-3150 in Patients With Primary Aldosteronism (clinicaltrials.gov) - May 16, 2017
P=N/A, N=40, Active, not recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
Recruiting --> Active, not recruiting | N=66 --> 4 | Trial primary completion date: Jul 2018 --> Jul 2019 Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A
- | Trial primary completion date: PHA-FMD: Primary Hyperaldosteronism and Ischemia-reperfusion Injury (clinicaltrials.gov) - Apr 18, 2017
P=N/A, N=40, Enrolling by invitation, Sponsor: Radboud University
Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A Trial primary completion date: Jul 2016 --> May 2017
- | Trial completion: LIPOCUSH: Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=90, Completed, Sponsor: Assistance Publique - H
Trial primary completion date: Jul 2016 --> May 2017 Recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: PostLapAdrnl: Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=13, Completed, Sponsor: Suez Canal University
Recruiting --> Completed Recruiting --> Completed | N=20 --> 13 | Trial primary completion date: Dec 2016 --> Jun 2016
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date: RE-KLAIM: Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=30, Enrolling by invitation, Sponsor: Corcept Therapeutics
Recruiting --> Completed | N=20 --> 13 | Trial primary completion date: Dec 2016 --> Jun 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- Biomarker, Enrollment open, Surgery: Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery (clinicaltrials.gov) - Dec 9, 2016
P=N/A, N=20, Recruiting, Sponsor: Corcept Therapeutics
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion, Trial primary completion date: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Dec 6, 2016
P2, N=8, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Dec 2016
- Trial completion, Enrollment change: ODPA: Optimizing Diagnosis Of Primary Aldosteronism (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=300, Completed, Sponsor: Chongqing Medical University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Dec 2016 Recruiting --> Completed | N=180 --> 300
- | Signifor (pasireotide) / Recordati
Trial completion: A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease (clinicaltrials.gov) - Nov 6, 2016
P2, N=26, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=180 --> 300 No longer recruiting --> Completed
- New trial: An Investigation Into the Effect of Liquorice Ingestion on the Salivary Cortisol to Cortisone Molar Ratio (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=12, Not yet recruiting, Sponsor: The Royal Wolverhampton Hospitals NHS Trust
- | Minnebro (esaxerenone) / Daiichi Sankyo
Enrollment open: Study of CS-3150 in Patients With Primary Aldosteronism (clinicaltrials.gov) - Oct 11, 2016
P3, N=40, Recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: PostLapAdrnl: Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=20, Recruiting, Sponsor: Suez Canal University
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Dec 2016
- Biomarker, New trial, Surgery: Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=20, Not yet recruiting, Sponsor: Corcept Therapeutics
- Korlym (mifepristone) / Corcept Therap
Trial completion, Enrollment change: Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism (clinicaltrials.gov) - Sep 30, 2016
P4, N=8, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Completed | N=20 --> 8
- hydrocortisone / Generic mfg.
New trial: VISECA: In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man (clinicaltrials.gov) - Sep 5, 2016
P=N/A, N=40, Completed, Sponsor: University Hospital, Bordeaux
- ||| Minnebro (esaxerenone) / Daiichi Sankyo
New P3 trial: Study of CS-3150 in Patients With Primary Aldosteronism (clinicaltrials.gov) - Aug 30, 2016
P3, N=40, Not yet recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
- Trial primary completion date: ODPA: Optimizing Diagnosis Of Primary Aldosteronism (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=180, Recruiting, Sponsor: Chongqing Medical University
Recruiting --> Completed | N=20 --> 8 Trial primary completion date: May 2016 --> Dec 2016
- Trial primary completion date: Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism (clinicaltrials.gov) - Jul 26, 2016
P2, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Oct 2016 --> Jul 2018
- Enrollment closed: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=45, Active, not recruiting, Sponsor: University of Michigan
Trial primary completion date: Oct 2016 --> Jul 2018 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=170, Completed, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015
- Trial primary completion date: LIPOCUSH: Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=90, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015 Trial primary completion date: Jun 2016 --> Sep 2016
- | Signifor (pasireotide) / Recordati
New P2 trial: SOM230 Ectopic ACTH-producing Tumors (clinicaltrials.gov) - May 24, 2016
P2, N=16, Recruiting, Sponsor: Cedars-Sinai Medical Center
- New trial: ODPA: Optimizing Diagnosis Of Primary Aldosteronism (clinicaltrials.gov) - May 2, 2016
P=N/A, N=180, Recruiting, Sponsor: Chongqing Medical University
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Phase classification: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Apr 21, 2016
P2, N=8, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Jun 2016 --> Sep 2016 Phase classification: P1/2 --> P2